IL-7 Reporter HEK 293 Cells
HEK-Blue™ IL-7 Cells | Unit size | Cat. code | Docs | Qty | Price |
---|---|---|---|---|---|
HEK 293 reporter cells for human and murine IL-7 cytokines |
3-7 x 10e6 cells |
hkb-il7 |
You may also need : QUANTI-Blue™ | View more associated products ▼
Notification: This product is for internal research use only. Additional rights may be available. Please visit InvivoGen’s Terms and Conditions.
HEK-Blue™ IL-7 Cells signaling pathway
Interleukin-7 Reporter Cells
HEK-Blue™ IL-7 cells were engineered from the human embryonic kidney HEK 293 cell line to detect bioactive interleukin-7 (IL-7) by monitoring the activation of the JAK/STAT5 pathway. IL-7 is a secreted cytokine that plays an essential role in B cell and T cell development and function [1-4].
Cell line description:
HEK-Blue™ IL-7 cells were generated by stable overexpression of the genes encoding the alpha chain of human IL-7 receptor (IL-7Rα), human IL-2Rγ, human JAK3, human STAT5b, and a STAT5-inducible secreted embryonic alkaline phosphatase (SEAP) reporter. STAT5-dependent SEAP activity is readily assessable in the supernatant using QUANTI-Blue™ Solution, a detection reagent. Of note, HEK-Blue™ IL-7 cells also respond to human type II interferons (IFN-γ; see Figures). However, they do not respond to human type I IFNs (IFN-α/IFN-β), as they are knock-out for IFNAR2.
Features of HEK-Blue™ IL-7 cells:
- Fully functional IL-7 signaling pathway
- Readily assessable STAT5-inducible SEAP reporter activity
- The stability for 20 passages has been verified
- Functionally tested and guaranteed mycoplasma-free
Applications of HEK-Blue™ IL-7 cells:
- Detection of human and murine IL-7
- Screening of anti-IL-7 and anti-IL-7R antibodies
References:
1. Lin J. et al., 2017. The role of IL-7 in Immunity and Cancer. Anticancer Res. 37(3):963-7.
2. Ribeir D. et al., 2018. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2(17):2199-213.
3. Mackall C.L. et al., 2011. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 11(5):330-42.
4. Barata J.T. et al., 2019. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 20(12):1584-93.
Specifications
Antibiotic resistance: Blasticidin, Hygromycin, Puromycin, Zeocin®
Growth medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™
Guaranteed mycoplasma-free
Specificity: human and murine IL-7
Detects human and murine IL-7: 100 pg - 100 ng/ml
This product is covered by a Limited Use License (See Terms and Conditions).
Back to the topContents
- 1 vial containing 3-7 x 106 cells
- 2 x 1 ml HEK-Blue™ Selection (250X concentrate)
- 1 ml of Puromycin (10 mg/ml)
- 1 ml Normocin™ (50 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
Shipped on dry ice (Europe, USA, Canada and some areas in Asia)
Details
Interleukin 7 (IL-7) is a secreted cytokine that plays an essential role in B cell and T cell development and function [1]. IL-7 signals through the heterodimeric cell surface IL-7 receptor (IL-7R) consisting of IL-7Rα (also called CD127) and IL-2Rγ (also called the common γ-chain or CD132).
The binding of IL-7 to its receptor triggers three main signaling pathways: JAK/STAT, PI3K, and MAPK/ERK [1‑3]. Of note, IL-7R-mediated signaling triggers proliferative and anti‑apoptotic signals mainly by activating the JAK/STAT pathway [1-3]. IL-7/IL-7R signaling, which regulates lymphocyte growth and survival, has been implicated in the development of malignancies and autoimmune diseases [1-4].
1. Lin J. et al., 2017. The role of IL-7 in Immunity and Cancer. Anticancer Res. 37(3):963-7.
2. Ribeir D. et al., 2018. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2(17):2199-213.
3. Mackall C.L. et al., 2011. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 11(5):330-42.
4. Barata J.T. et al., 2019. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 20(12):1584-93.